株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

線維筋痛症(FM)治療の世界市場 - 産業考察、動向、見通し、市場機会の分析 2018年~2026年

Fibromyalgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 865083
出版日 ページ情報 英文 176 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
線維筋痛症(FM)治療の世界市場 - 産業考察、動向、見通し、市場機会の分析 2018年~2026年 Fibromyalgia Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2019年05月10日 ページ情報: 英文 176 Pages
概要

線維筋痛症(FM)は全身に重度の痛みを引き起こす慢性的な神経障害です。線維筋痛症(FM)の病因は知られていませんが、遺伝的要因、身体的要因など様々な要因によって引き起こされると推論されています。線維筋痛症(FM)市場は、創薬研究の活発化や新薬の上市などによって成長が促進される見通しです。

当レポートでは、世界の線維筋痛症(FM)治療市場を調査し、市場の概要、医薬品クラス・流通チャネル・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場範囲

  • レポート範囲
  • 市場の定義と範囲
  • エグゼクティブサマリー
  • 市場スニペット:医薬品クラス別
  • 市場スニペット:流通チャネル別
  • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
  • 成長要因
  • 阻害要因
  • 市場機会
  • 影響分析
  • パイプライン分析
  • 特許訴訟
  • 償還制度
  • 特許情勢
  • PEST分析
  • ファイブフォース分析

第4章 世界の線維筋痛症(FM)治療市場:医薬品クラス別

  • イントロダクション
  • 抗うつ薬
    • ミルナシプラン(サベラなど)
    • デュロキセチン(シンバルタなど)
    • その他
  • 抗てんかん薬
    • プレガバリン(リリカなど)
    • その他
  • 筋弛緩剤
  • 鎮痛薬
  • その他

第5章 世界の線維筋痛症(FM)治療市場:流通チャネル別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 世界の線維筋痛症(FM)治療市場:地域別

  • イントロダクション
  • 北米
    • 北米
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • ロシア
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • ASEAN
    • オーストラリア
    • 韓国
    • その他
  • 中南米
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他
  • アフリカ
    • 中央アフリカ
    • 南アフリカ
    • 北アフリカ
  • 中東
    • 湾岸協力会議(GCC)
    • イスラエル
    • その他

第7章 競争環境

  • ヒートマップ解析
  • 企業プロファイル
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Novartis AG
  • Allergan plc.
  • Sun Pharmaceutical Industries Ltd.
  • Aptinyx, Inc.
  • Prismic Pharmaceuticals, Inc.
  • Innovative Med Concepts, Inc.
  • Intec Pharma Ltd.
  • アステラス製薬

第8章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insights
目次

Fibromyalgia, also called fibromyalgia syndrome, is a chronic neurologic disorder, which causes severe pain all over the body. The cause of fibromyalgia is unknown, however, it can be caused due to various factors, including genetics cause, physical or emotional trauma or due to infections. The symptoms related to fibromyalgia includes widespread pain, severe fatigue, sleep problems, cognitive difficulties, and others. Various medications such as antidepressant drugs, antiepileptic drugs, muscle relaxants, and analgesics are used for the management and treatment of fibromyalgia.

Market Dynamics

Key players in the market are focusing on frequent research and development activities for development of novel medications for fibromyalgia treatment. Launch of novel drugs in the market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the forecast period. For instance, drug candidate IMC-1 is being developed by Innovative Med Concepts, which received fast track designation from the U.S. FDA in 2016

In December 2018, Aptinyx Inc. announced positive results from an interim analysis of an exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20 mg and 200 mg, as well as placebo, over the course of six weeks.

In 2017, Innovative Med Concepts announced that the Journal of Pain Research published the key topline results from the Phase 2 PRID-201 trial of IMC-1 for the treatment of fibromyalgia. This 16 week, randomized double-blinded, placebo-controlled study was conducted at 12 research centers in the U.S. and enrolled 143 patients with fibromyalgia, as defined by the ACR 2010 criteria. The PRID-201 study demonstrated that patients randomized to IMC-1 (celecoxib+famciclovir) experienced a significant decrease in fibromyalgia-related pain vs patients randomized to placebo.

Moreover, over the past few years, leading generic manufacturers such as Sun Pharmaceutical Industries Ltd., Mylan N.V., and Teva Pharmaceuticals Industries Ltd. have launched generic drugs for fibromyalgia treatment in the market.

Launch of generic versions of branded fibromyalgia drugs is expected to affect the revenue of branded drugs. However, it is expected to increase adoption and affordability of drugs and support fibromyalgia treatment market growth in the near future.

For instance, in December 2013, Sun Pharmaceutical Industries Ltd. announced that the U.S. FDA granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta, Duloxetine Delayed-Release Capsules USP, 20 mg, 30 mg, and 60 mg.

Key features of the study:

  • This report provides in-depth analysis of fibromyalgia treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the global fibromyalgia treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Eli Lilly and Company, Pfizer, Inc., Novartis AG, Allergan plc, Sun Pharmaceutical Industries Ltd., Aptinyx, Inc., Prismic Pharmaceuticals, Inc., Innovative Med Concepts, Inc., Intec Pharma Ltd., and Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global fibromyalgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the fibromyalgia treatment market

Detailed Segmentation:

  • Global Fibromyalgia Treatment Market, By Drug Class :
    • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
    • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
    • Muscle Relaxants
    • Analgesics
    • Others (Including Pipeline Drugs)
  • Global Fibromyalgia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Fibromyalgia Treatment Market, By Region:
    • North America
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class :
      • Antidepressants
      • Milnacipran (Savella and Other Generics)
      • Duloxetine (Cymbalta and Other Generics)
      • Others
      • Antiepileptics
      • Pregabalin (Lyrica and Other Generics)
      • Others
      • Muscle Relaxants
      • Analgesics
      • Others (Including Pipeline Drugs)
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • Central Africa
      • South Africa
      • North Africa
  • Company Profiles
    • Eli Lilly and Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • Novartis AG
    • Allergan plc.
    • Sun Pharmaceutical Industries Ltd.
    • Aptinyx, Inc.
    • Prismic Pharmaceuticals, Inc.
    • Innovative Med Concepts, Inc.
    • Intec Pharma Ltd.
    • Astellas Pharma Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Patent Litigations
    • Reimbursement
    • Patent Landscape (ANDA/NDA Intelligence)
    • PEST Analysis
    • Porter's Analysis

4. Global Fibromyalgia Treatment Market, By Drug Class, 2016 - 2026 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Segment Trends
    • Milnacipran (Savella and Other Generics)
    • Duloxetine (Cymbalta and Other Generics)
    • Others
    • Antiepileptics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Segment Trends
    • Pregabalin (Lyrica and Other Generics)
    • Others
    • Muscle Relaxants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Analgesics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Others (Including Pipeline Drugs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

5. Global Fibromyalgia Treatment Market, By Distribution Channel, 2016 - 2026 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

6. Global Fibromyalgia Treatment Market, By Region, 2016 - 2026 (US$ Mn)

    • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017-2026
    • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Aptinyx, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Prismic Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Innovative Med Concepts, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Intec Pharma Ltd
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Astellas Pharma Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact
Back to Top